NO20081325L - Nye doseringsformuleringer - Google Patents

Nye doseringsformuleringer

Info

Publication number
NO20081325L
NO20081325L NO20081325A NO20081325A NO20081325L NO 20081325 L NO20081325 L NO 20081325L NO 20081325 A NO20081325 A NO 20081325A NO 20081325 A NO20081325 A NO 20081325A NO 20081325 L NO20081325 L NO 20081325L
Authority
NO
Norway
Prior art keywords
relates
dosage formulations
composition
new dosage
tablet composition
Prior art date
Application number
NO20081325A
Other languages
English (en)
Other versions
NO340473B1 (no
Inventor
Navnit Hargovindas Shah
Susanne Page
Hashim A Ahmed
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37671050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081325(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20081325L publication Critical patent/NO20081325L/no
Publication of NO340473B1 publication Critical patent/NO340473B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Abstract

I Oppfinnelsen angår en fremgangsmåte for fremstilling av et farmasøytisk tablettpreparat, hvor den aktive farmasøytiske bestanddel med formel I hvor definisjonene er som beskrevet i krav 1 eller farmasøytisk akseptable syreaddisjonssalter derav og en vannoppløselig poloksamer sammen blir prosessert ved varmsmelte-ekstrusjon før blanding med de andre bestanddeler og hvor tablettpreparatet deretter kan belegges med et preparat omfattende et filmbeleggingssystem med umiddelbar frigjøring og renset vann. Oppfinnelsen angår også farmasøytiske preparater fremstilt ved en slik metode.
NO20081325A 2005-09-23 2008-03-13 Farmasøytisk tablettpreparat samt fremgangsmåte for fremstilling av samme NO340473B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71979305P 2005-09-23 2005-09-23
PCT/EP2006/066310 WO2007039420A1 (en) 2005-09-23 2006-09-13 Novel dosage formulation

Publications (2)

Publication Number Publication Date
NO20081325L true NO20081325L (no) 2008-06-18
NO340473B1 NO340473B1 (no) 2017-04-24

Family

ID=37671050

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081325A NO340473B1 (no) 2005-09-23 2008-03-13 Farmasøytisk tablettpreparat samt fremgangsmåte for fremstilling av samme

Country Status (26)

Country Link
US (3) US20070071813A1 (no)
EP (1) EP1928427B1 (no)
JP (2) JP5523706B2 (no)
KR (1) KR20080043852A (no)
CN (2) CN101267808A (no)
AR (1) AR056198A1 (no)
AT (1) ATE453384T1 (no)
AU (1) AU2006298898B2 (no)
BR (1) BRPI0616108A2 (no)
CA (1) CA2623237C (no)
DE (1) DE602006011485D1 (no)
DK (1) DK1928427T3 (no)
ES (1) ES2335922T3 (no)
HK (1) HK1198914A1 (no)
HR (1) HRP20100111T1 (no)
IL (1) IL189929A (no)
MY (1) MY143784A (no)
NO (1) NO340473B1 (no)
NZ (1) NZ566419A (no)
PL (1) PL1928427T3 (no)
PT (1) PT1928427E (no)
RU (1) RU2431473C2 (no)
SI (1) SI1928427T1 (no)
TW (1) TWI375572B (no)
WO (1) WO2007039420A1 (no)
ZA (1) ZA200802272B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2404919T1 (sl) 2005-11-08 2013-12-31 Vertex Pharmaceuticals Incorporated Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CA2686838C (en) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulators of cftr
DE102007027067A1 (de) * 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
CA2706920C (en) 2007-12-07 2018-02-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
PT2639222T (pt) 2007-12-07 2016-11-01 Vertex Pharma Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos
AU2009203627A1 (en) * 2008-01-11 2009-07-16 Cipla Limited Solid pharmaceutical dosage form
ES2647531T3 (es) 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Derivados de heteroarilo como moduladores de CFTR
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
JP5917964B2 (ja) * 2012-03-19 2016-05-18 富士ゼロックス株式会社 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム
WO2015068744A1 (ja) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
PL3068392T3 (pl) 2013-11-12 2021-07-19 Vertex Pharmaceuticals Incorporated Proces wytwarzania kompozycji farmaceutycznych do leczenia chorób, w których pośredniczy cftr
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
US11771655B2 (en) * 2014-09-08 2023-10-03 University Of Central Lancashire Solid dosage form production
JP6494757B2 (ja) 2014-11-18 2019-04-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ハイスループット試験高速液体クロマトグラフィーを行うプロセス
CN104586770A (zh) * 2014-12-30 2015-05-06 山东博迈康药物研究有限公司 一种盐酸帕唑帕尼的热熔挤出制剂及其制备方法
ES2948307T3 (es) 2017-11-14 2023-09-08 Merck Sharp & Dohme Llc Nuevos compuestos de biarilo sustituidos como inhibidores de indolamina 2,3-dioxigenasa (IDO)
CN108159008B (zh) * 2018-02-27 2021-03-23 河北化工医药职业技术学院 缬沙坦咀嚼片的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
EP0089765A3 (en) 1982-03-17 1984-05-23 Smith Kline & French Laboratories Limited Pyridine derivatives
JPS60184008A (ja) * 1984-03-02 1985-09-19 Eisai Co Ltd テオフイリンまたはアミノフイリン含有組成物
US4745123A (en) 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1994003429A1 (en) * 1992-07-31 1994-02-17 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
AU6807994A (en) 1993-05-28 1994-12-20 Taisho Pharmaceutical Co., Ltd. Medicinal use of pyridine derivative
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
JP3071467B2 (ja) * 1993-12-29 2000-07-31 メルク シヤープ エンド ドーム リミテツド 置換モルホリン誘導体およびその治療剤としての使用
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DK0764163T3 (da) 1994-06-06 2002-02-04 Warner Lambert Co Tachykinin (NK1) receptor-antagonister
WO1996000213A1 (fr) 1994-06-24 1996-01-04 Taisho Pharmaceutical Co., Ltd. Derive de pyridine
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6294537B1 (en) * 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
ATE242243T1 (de) 1995-03-24 2003-06-15 Takeda Chemical Industries Ltd Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten
CN1168719C (zh) 1996-03-29 2004-09-29 辉瑞大药厂 6-苯基吡啶-2-基胺衍生物以及药物组合物和用途
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
AU4885097A (en) 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
JPH11189546A (ja) 1997-12-25 1999-07-13 Saitama Daiichi Seiyaku Kk 経皮吸収促進剤
JPH11189548A (ja) * 1997-12-25 1999-07-13 Toshio Sato 無晶性医薬組成物及びその製造方法
KR100514236B1 (ko) 1999-02-24 2005-09-13 에프. 호프만-라 로슈 아게 페닐 유도체 및 피리디닐 유도체
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
DK1103545T3 (da) * 1999-11-29 2004-03-15 Hoffmann La Roche 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
DE60201988T2 (de) * 2001-05-03 2005-12-15 F. Hoffmann-La Roche Ag Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
KR100810320B1 (ko) 2005-06-16 2008-03-04 삼성전자주식회사 디지털 방송 재생기가 방송 중에 제공되는 전화번호를이용하여 발신하는 방법 및 그 디지털 방송 시스템

Also Published As

Publication number Publication date
NZ566419A (en) 2010-03-26
US20110070303A1 (en) 2011-03-24
ATE453384T1 (de) 2010-01-15
BRPI0616108A2 (pt) 2011-06-07
RU2008109823A (ru) 2009-10-27
HK1198914A1 (en) 2015-06-19
RU2431473C2 (ru) 2011-10-20
AU2006298898B2 (en) 2011-06-30
JP2009508907A (ja) 2009-03-05
CA2623237A1 (en) 2007-04-12
IL189929A0 (en) 2008-08-07
CN101267808A (zh) 2008-09-17
NO340473B1 (no) 2017-04-24
TW200803922A (en) 2008-01-16
CN103893145A (zh) 2014-07-02
US20130189362A1 (en) 2013-07-25
EP1928427A1 (en) 2008-06-11
US20070071813A1 (en) 2007-03-29
PL1928427T3 (pl) 2010-06-30
SI1928427T1 (sl) 2010-03-31
ZA200802272B (en) 2009-01-28
DK1928427T3 (da) 2010-03-08
IL189929A (en) 2012-12-31
EP1928427B1 (en) 2009-12-30
ES2335922T3 (es) 2010-04-06
HRP20100111T1 (hr) 2010-04-30
PT1928427E (pt) 2010-03-01
AR056198A1 (es) 2007-09-26
JP2013049686A (ja) 2013-03-14
AU2006298898A1 (en) 2007-04-12
TWI375572B (en) 2012-11-01
KR20080043852A (ko) 2008-05-19
JP5523706B2 (ja) 2014-06-18
DE602006011485D1 (de) 2010-02-11
MY143784A (en) 2011-07-15
US8852634B2 (en) 2014-10-07
WO2007039420A1 (en) 2007-04-12
CA2623237C (en) 2013-07-09

Similar Documents

Publication Publication Date Title
NO20081325L (no) Nye doseringsformuleringer
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
EP4293009A3 (en) Fenfluramine compositions and methods of preparing the same
WO2008089151A3 (en) High dose film compositions and methods of preparation
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
EA200970942A1 (ru) Экстракт пажитника сенного (trigonella foenum-graecum)
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
WO2004108162A3 (en) Controlled release pharmaceutical composition
WO2013052545A4 (en) Hair care compositions and methods of use
WO2005000232A3 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
RU2012127776A (ru) Растворимые пленки, содержащие высокие концентрации неионных поверхностно-активных веществ, таких как полисорбаты, для увеличения высоких нагрузок твердых продуктов
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
EE200200504A (et) Farmatseutilised preparaadid
WO2009084036A3 (en) Composition for treatment of viral infections
WO2010080339A4 (en) Phenylephrine formulations with improved stability
AU2005238141A8 (en) Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
RU2015138710A (ru) Жевательная композиция для перорального приема и способ ее получения
WO2020025742A9 (en) Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome
CN107213131A (zh) 用于治疗心血管疾病固体制剂的包衣技术
CN105193769A (zh) 一种盐酸苯海拉明口腔速溶膜剂的制备方法
WO2011080570A3 (en) Extended release pharmaceutical composition comprising linezolid and process for preparing the same
RU2011145436A (ru) Композиции с немедленным высвобождением лекарственного средства
ATE269352T1 (de) 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung